HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Jiangsu Hengrui Medicine (600276 CH) - Q3 Performance Improved with Promising Innovative Pipeline

JW Therapeutics - Concerns Are in the Short Term but Still Promising in the Long Term

Insights On China Healthcare Policy - 4+7: New Volume-Based Purchasing Policy

Equity Bottom-Up

Hangzhou Tigermed Consulting C / Equity Bottom-Up

<a target="_blank"></a><a href="https://www.smartkarma.com/entities/hangzhou-tigermed-consulting-h" target="_blank" data-smartkarma-citation="entities:29212:1" rel="noopener">Hangzhou Tigermed Consulting (H) (3347 HK)</a> released the third quarter report of 2020. In the first three quarters of 2020, Q1-Q3 accumulated revenue reached RMB2.33 billion, with a YoY growth rate of 13.27%. Net income attributed to shareholders in the first three quarters reached RMB1.318 billion, up 149.57% YoY. Net income after deducting non-recurring gains and losses in Q1-Q3 was RMB498 million, up 13.57% YoY. The company's Q3 single quarter revenue reached RMB848 million, up 22.31% YoY. Net income attributed to shareholders in Q3 was RMB319 million, up 81.37% YoY. Net income after deducting non-recurring gains and losses in Q3 reached RMB195 million, up 29.35% YoY. Tigermed has gradually recovered from the epidemic with strong performance in Q3. 
<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/169/276/original/image_94552562551604465156309.png?1604465157" class="editor-image img-responsive" data-smartkarma-image-id="169276"></figure>
Source: WIND

Hangzhou Tigermed Consulting (H) (3347 HK) released the third quarter report of 2020. In the first three quarters of 2020, Q1-Q3 accumulated revenue reached RMB2.33 billion, with a YoY growth rate of 13.27%. Net income attributed to shareholders in the first three quarters reached RMB1.318 billion, up 149.57% YoY. Net income after deducting non-recurring gains and losses in Q1-Q3 was RMB498 million, up 13.57% YoY. The company's Q3 single quarter revenue reached RMB848 million, up 22.31% YoY. Net income attributed to shareholders in Q3 was RMB319 million, up 81.37% YoY. Net income after deducting non-recurring gains and losses in Q3 reached RMB195 million, up 29.35% YoY. Tigermed has gradually recovered from the epidemic with strong performance in Q3. 

Source: WIND

Hangzhou Tigermed Consulting (A) (300347 CH)

Tigermed(300347.CN/03347.HK) - 3분기 실적 회복, 낙관적 미래 전망